Baxter released the first antimicrobial luer IV connector, dubbed V-Link, earlier this year, a device known to be effective against MRSA, Pseudomonas aeruginosa and Enterobacter cloacae. The V-Link connector employs an antimicrobial silver coating Baxter calls VitalShield. The VitaShield coated connector has been shown to kill 99.9% of pathogens that can cause IV related bloodstream infections.
Today, Baxter received FDA clearance to expand their labeling, based on confirmation of device’s ability to combat three additional pathogens: vancomycin-resistant Enterococcus faecalis (VRE), Escherichia coli (E. coli) and Staphylococcus epidermidis (coagulase negative).
Francois Lebel, MD, vice president of Clinical and Medical Affairs for Baxter’s Medication Delivery business said:
“The revised labeling and expanded indications for use further validate the broad spectrum antimicrobial coverage and effectiveness of V-Link with VitalShield in lowering the risk of pathogen contamination.”
Timing for this product seems ideal, as beginning in October the Centers for Medicare and Medicaid Services (CMS) will not reimburse U.S. hospitals for costs required to treat healthcare-associated infections!
Press release: Baxter’s Antimicrobial IV Technology Now Shown to Kill Six Common Pathogens, Including MRSA and VRE…
Product page: V-Link Luer-Activated Device with VitalShield Protective Coating…